Citigroup Maintains Buy on Surgery Partners, Lowers Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Jason Cassorla has maintained a Buy rating on Surgery Partners (NASDAQ:SGRY) but has lowered the price target from $43 to $42.

February 27, 2024 | 5:30 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Citigroup maintains a Buy rating on Surgery Partners but lowers the price target from $43 to $42.
While the reduction in the price target from $43 to $42 by Citigroup might seem negative at first glance, the maintenance of a Buy rating indicates a continued positive outlook on the company's future performance. The slight adjustment in the price target could reflect minor concerns or market adjustments rather than a significant change in the company's fundamentals or growth prospects. Investors might see this as a minor adjustment rather than a cause for concern.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100